JPMorgan Chase & Co. set a €130.00 ($151.16) price objective on MorphoSys (ETR:MOR) in a report published on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently weighed in on MOR. Royal Bank of Canada set a €130.00 ($151.16) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Friday, August 9th. Goldman Sachs Group set a €114.00 ($132.56) target price on shares of MorphoSys and gave the stock a neutral rating in a research note on Wednesday, August 7th. Berenberg Bank set a €150.00 ($174.42) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Monday, September 9th. HSBC set a €81.00 ($94.19) target price on shares of MorphoSys and gave the stock a sell rating in a research note on Friday, August 16th. Finally, Deutsche Bank set a €133.00 ($154.65) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of €119.67 ($139.15).

Shares of MOR opened at €105.70 ($122.91) on Wednesday. MorphoSys has a fifty-two week low of €76.45 ($88.90) and a fifty-two week high of €114.70 ($133.37). The firm’s 50 day moving average price is €107.61 and its 200 day moving average price is €93.33. The company has a market cap of $3.34 billion and a P/E ratio of -80.02. The company has a quick ratio of 7.40, a current ratio of 7.62 and a debt-to-equity ratio of 8.61.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Recommended Story: What is dividend yield?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.